A phase I/IIa trial of VBI-1901 in patients with recurrent glioblastoma multiforme
Phase of Trial: Phase I/II
Latest Information Update: 10 Nov 2017
At a glance
- Drugs VBI 1901 (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; First in man
- Sponsors VBI Vaccines
- 10 Nov 2017 According to a VBI Vaccines media release, the company anticipates initiate enrollment the fourth quarter of 2017.
- 28 Aug 2017 According to a VBI Vaccines media release, the company expects to initiate the enrollment in this study in the second half of 2017.
- 15 Aug 2017 According to a VBI Vaccines media release, the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug Application (IND) for VBI-1901 and the comapny will initiate Phase I/2a study of VBI-1901 in patients with recurrent GBM in the second half of 2017.